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ABSTRACT
In patients with normogonadotropic anovulation, either with or
without polycystic ovary syndrome (PCOS), factors interfering with
FSH action may be involved in arrested follicle development. The aim
of this study is to assess whether factors inhibiting FSH receptor
activation are elevated in serum or follicular fluid from anovulatory
patients, as compared with regularly cycling women. For this pur-
pose, a Chinese hamster ovary cell line, stably transfected with the
human FSH receptor, has been applied. FSH-stimulated cAMP se-
cretion in culture medium was measured in the presence of serum or
follicular fluid. Chinese hamster ovary cells were stimulated with a
fixed concentration of FSH (3 or 6 mIU/mL) to mimic FSH levels in
serum or follicular fluid. Samples were added in concentrations rang-
ing from 3–90% vol/vol to approach protein concentrations occurring
in serum or follicular fluid.
In the presence of 10% vol/vol serum from regularly cycling women
(n 5 8), FSH-stimulated cAMP production was inhibited to 42 6 2%
(mean 6 SEM of 2 experiments, each performed in duplicate) of cAMP
production in the absence of serum, whereas a similar cAMP level (up
to 38 6 4% of the serum-free level) was observed at higher concen-
trations of serum (30–90% vol/vol). The inhibition of FSH-stimulated
cAMP production in the presence of serum samples from normogo-
nadotropic anovulatory patients, without (n 5 13) or with (n 5 16)
PCOS, was similar to controls. Follicular fluid samples (n 5 57)
obtained during the follicular phase in 25 regularly cycling women
and follicular fluid samples (n 5 25) from 5 PCOS patients were tested
in a slightly modified assay system. In the presence of 10 or 30%
(vol/vol) follicular fluid, FSH-stimulated cAMP levels were decreased
to 68 6 2% and 55 6 2% (mean 6 SEM of a single experiment in
triplicate) of the cAMP levels in the absence of follicular fluid, re-
spectively. There was no correlation between the degree of cAMP
inhibition and follicle size, steroid content (androstenedione or es-
tradiol concentrations), or menstrual cycle phase. Furthermore, no
differences in inhibition were found, comparing PCOS follicles with
size- and steroid content-matched follicles obtained during the normal
follicular phase.
It is concluded that inhibition of FSH receptor activation by pro-
teins present in serum or follicular fluid is constant (60 and 40%,
respectively) and independent from the developmental stage of the
follicle, either during the normal follicular phase or in patients with
normogonadotropic anovulation. Inhibition of FSH receptor activa-
tion may be of limited significance for normal and arrested follicle
development. (J Clin Endocrinol Metab 82: 1325–1331, 1997)
ALARGE proportion of women presenting with anovu-lation and infertility exhibit serum FSH concentra-
tions within the normal range. The majority of these patients
can be diagnosed as suffering from polycystic ovary syn-
drome (PCOS), on the basis of the sonographic appearance
of the ovaries and endocrine serum parameters (1, 2). A
common finding in PCOS is normal early follicle develop-
ment, whereas selection of the dominant follicle is absent (3,
4). The underlying mechanism of follicle maturation arrest is
unclear. The possibility of abnormal circulating FSH could be
ruled out by demonstrating normal bioactivity, as assessed
by an in vitro rat granulosa cell aromatase bioassay (1, 5).
Because normal follicular growth, selection, and ovulation
can be induced in some PCOS patients by administration of
exogenous gonadotropins (6) and granulosa cells of these
patients show normal (7) or even elevated (8) FSH-induced
estradiol (E2) production in vitro, it may be postulated that
locally active factors, rather than defective granulosa cells,
are involved in arrested follicle growth in PCOS patients.
There are many indications that local regulation of FSH
action may play a role in normal and disturbed follicular
development (9–12). Growth factors, such as insulin-like
growth factors (IGF) (13) or activin (14), act as potentiators
of FSH action in vitro. Ongoing growth of the dominant
follicle, despite a decrease in FSH serum levels in the late
follicular phase (LFP) (15), may be attributed to the enhance-
ment of FSH action by these growth factors, acting in a para-
or autocrine fashion. On the other hand, growth factors may
also exert inhibitory actions, as has been described for epi-
dermal growth factor (16, 17). Although stimulatory or in-
hibitory effects of growth factors are mediated by their spe-
cific receptors and pathways, inhibition of FSH action may
also be caused by specific FSH receptor inhibitors (12). Sev-
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eral studies report the presence of specific FSH receptor-
binding inhibitors of unknown origin in human serum (18,
19) and follicular fluid (20–23). Part of these inhibitors may
be of immunological nature (24) and could lead to premature
ovarian failure. It may be postulated that partial inhibition of
FSH receptor activation causes arrested follicular growth and
absent dominant follicle selection in PCOS patients.
The aim of this study was to assess the level of inhibitors
of FSH receptor activation in serum and follicular fluid of
normogonadotropic anovulatory patients, with or without
PCOS, as compared with normal controls. For this purpose,
a Chinese hamster ovary (CHO)-cell line, transfected with
the human FSH receptor (25), has been used. Inhibition of
FSH-stimulated cAMP production has been studied at phys-
iological concentrations of FSH and at a range of concentra-
tions of serum or follicular fluid.
Materials and Methods
Hormones and reagents
Recombinant human FSH (recFSH: Org 32489, bioactivity 8413 IU/
mg, as assessed by in vivo bioassay relative to reference preparation IS
70/45; immunoactivity 12,000 IU/mg) was a generous gift from NV
Organon (Oss, The Netherlands). Isobutyl-methyl-xanthine (IBMX) was
purchased from Sigma Chemie (Bornhem, Belgium).
Cell cultures
A CHO cell line, stably transfected with recFSH receptor comple-
mentary DNA, was generously provided by NV Organon). CHO cells
were cultured as described previously (25). In brief, cells (104 cells/cm2)
were plated on 48-well culture dishes in DMEM/Ham-F12 (1:1) (GIBCO
Europe BV, Breda, The Netherlands) with the addition of 100 U/mL
penicillin and 100 mg/mL streptomycin and 10% vol/vol FCS (Sebak
GmbH, Adenbach, Germany). After 2 days, the CHO cells reached
confluence and were used for the FSH receptor activation assay.
Serum samples
Serum samples were collected from 29 anovulatory patients, attend-
ing the Dijkzigt Hospital outpatient clinic for infertility evaluation. In-
clusion criteria were: infertility, oligo- or amenorrhea, and serum FSH
levels within normal limits (1–10 IU/L). The involvement of human
subjects in these investigations was approved by the Ethics Review
Committee of the Dijkzigt Academic Hospital and Erasmus University
Medical School, and informed consent was obtained from all subjects
participating. Patient samples were divided into 2 subgroups repre-
senting normogonadotropic anovulation, either without (n 5 13) or with
PCOS (n 5 16). Patients were diagnosed as having PCOS on the basis
of rigid criteria, including elevated serum LH levels (.8 IU/L) and
elevated serum androgens [androstenedione (AD) more than 15.0
nmol/L and/or testosterone (T) more than 3.0 nmol/L and/or a free
androgen index (FAI: [T 3 100]/steroid hormone-binding globulin ra-
tio) more than 5] (1) and polycystic ovaries, as assessed by transvaginal
sonography (26). Patients diagnosed as anovulatory (without PCOS) had
normal LH and androgen concentrations and normal ovaries on ultra-
sound. In addition, FSH levels in all serum samples were measured by
immunoradiometric assay (IRMA-FSH; Medgenix, Fleurus, Belgium).
Serum samples selected for this study had IRMA-FSH levels between 3
and 6 IU/L, to fulfill the FSH receptor activation assay requirements (see
below).
Normal ovulatory women in the early follicular phase (EFP) of the
menstrual cycle (8–10 days before the LH surge) served as controls (n 5
8). These volunteers were recruited by advertisement and were paid for
their participation (15). Mean cycle length was 28 6 2 sd days. Again,
control samples exhibiting IRMA-FSH levels between 3 and 6 IU/L were
chosen. See Table 1 for population and endocrine characteristics of all
subjects studied.
Follicular fluid samples
Follicle fluid was obtained from 22 women undergoing laparotomy
for reversal of tubal sterilization or adhesiolysis and from 3 women
undergoing laparoscopic tubal ligation. Informed consent was obtained
from all subjects participating. All subjects were regularly cycling
women with a mean cycle length of 27 6 2 sd days and of normal weight
(mean body mass index: 24 6 2 sd kg/m2). Mean age was 33 6 4 sd yr,
and all patients had a history of proven fertility. The day of the menstrual
cycle, at the time of the follicle puncture, was assessed from the day of
onset of the last menstrual period. Follicle fluid was obtained from
individual follicles (between 1 and 8 per patient; Fig. 1) and assayed for
E2 and AD as described previously (27). Follicular fluid samples were
classified into 5 different categories. The classification was on the basis
of 3 criteria: 1) the menstrual cycle phase in which patients underwent
surgery (EFP: cycle day 1–8 or LFP: cycle day 9–15); 2) follicle size
(nondominant: ,10 mm or dominant: $10 mm) (15, 27); and 3) AD/E2
ratio (healthy: ,4, or atretic: $4) (27, 28).
In addition, follicular fluid was obtained from five anovulatory, in-
fertile patients diagnosed as PCOS (diagnostic criteria the same as for
PCOS serum study). In two patients, two to three follicles were punc-
tured during laparoscopy. In one patient, six follicles were punctured
during elective surgery for fallopian tube correction. The remaining two
patients were stimulated with human menopausal gonadotropins for
infertility treatment. Because of multiple follicle development (more
than three follicles larger than 16 mm), stimulation was canceled. In
these patients, follicular fluid samples (five and nine, respectively) were
obtained through sonographically guided transvaginal punction. See
TABLE 1. Population and endocrine characteristics (mean 6 SD)








Age (yr) 25.5 6 4.2 30.4 6 6.4 26.9 6 5.3
BMI (kg/m2) 23.2 6 2.4 25.4 6 5.1 26.0 6 3.4
IRMA-FSH (IU/L) 5.4 6 0.2 4.3 6 1.2 4.8 6 0.8
IRMA-LH (IU/L) 3.5 6 1.3 4.0 6 1.9 10.5 6 1.2
Testosterone (nmol/L) 1.8 6 0.5 1.3 6 0.5 3.1 6 1.2
Androstenedione (nmol/L) 10.5 6 3.2 7.9 6 2.8 23.9 6 9.8
FAI 3.1 6 1.0 2.6 6 1.3 10.3 6 5.7
BMI, Body mass index (weight/square length); IRMA-FSH, immu-
noreactive FSH; IRMA-LH, immunoreactive LH; FAI, free androgen
index, calculated as (testosterone 3 100)/steroid hormone binding
globulin.
FIG. 1. Follicle diameter and menstrual cycle day in 57 follicles, ob-
tained from 25 normally cycling women. E, Healthy follicles (AD/E2
ratio , 4); 1, atretic follicles (AD/E2 ratio $ 4). Numbers on top
indicate number of subjects from whom samples were obtained on a
given cycle day.
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Table 2 for the classification and endocrine characteristics of the follic-
ular fluid samples used.
FSH-receptor activation assay
Validation of this assay has been described previously (25). In brief,
cultured CHO cells were incubated in 48-well culture dishes. The culture
medium was replaced by FCS-free DMEM/Ham-F12 with 0.1 mmol/L
IBMX and various concentrations of human serum or follicular fluid
(3–90% vol/vol), and cells were stimulated with recFSH. After 4 h of
incubation, medium was removed and stored at 220 C until analysis for
cAMP.
For the measurement of the inhibitory effect in the serum samples, a
fixed concentration of 6 mIU/mL FSH was used. To obtain this con-
centration of FSH in each dilution of the serum samples, endogenous
FSH serum levels (range: 3–6 IU/L) were corrected by the addition of
recFSH.
A pool of hypogonadotropic serum, obtained from high-dosed (50 mg
ethinyl-E2 daily) combined oral contraceptive pill users, served as a
control in each assay. The FSH level of this serum pool was less than 0.5
IU/L, as assessed by IRMA.
Each serum sample was tested in duplicate in two independent FSH
receptor activation assays. Results are expressed as the percentage of the
cAMP production, relative to the cAMP response in serum free condi-
tions, which was set at 100% at the given stimulatory dose of recFSH (6
mIU/mL).
Because of small volumes available, the CHO assay was adapted, to
allow analysis of follicular fluid samples. For this purpose, CHO cells
were cultured in 96-multiwell dishes, at a cell density of 104 cells/cm2,
and incubated in a vol of 50 mL/well. The sensitivity for recFSH and the
degree of stimulation of the cAMP production in this assay, applying
small volumes, was similar to the assay performed in 48-wells (data not
shown).
The small volumes of individual follicular fluid samples allowed for
testing at only two concentrations (10 and 30% vol/vol) in triplicate. The
inhibitory effect of follicular fluid was assessed by stimulating CHO cells
with 3 mIU/mL recFSH, instead of 6 mIU/mL. This FSH concentration
was taken, to approximate the endogenous FSH levels in the follicular
fluid samples (4, 8, 29, 30). Because volumes of the tested follicular fluid
samples were small (in some cases only 30 mL), it was not possible to
measure the FSH content.
In all experiments, DNA content of the wells was measured by a
fluorometric method, as described previously (31). The intraassay co-
efficient of variation for DNA content/well was less than 12%. In all FSH
receptor activation assays, the cAMP levels were normalized on the basis
of the DNA content of the wells.
RIAs
cAMP in the media was assayed as described previously (32). In brief,
after acetylation, the samples were incubated overnight with cAMP
antibody (purchased from Prof. Dr. J. Stoof, Free University, Amster-
dam, The Netherlands). The assay was validated for the use of culture
media and corrected for addition of serum in the samples. All samples
were assayed in duplicate. Sensitivity of the assay was 0.125 pmol/mL.
Inter- and intraassay coefficients of variation were 20% and 8%,
respectively.
E2 and AD in follicular fluid were measured in a 1:100 dilution of the
samples, as described previously (27). E2 concentrations were estimated
using an RIA kit (Diagnostic Products Corporation, Los Angeles, CA);
AD concentrations were estimated using antisera and diethylether-hex-
ane extraction, as described previously (33).
Data analysis
Experimental data are presented as the mean 6 sem if they are
normally distributed and as median and range if distributed otherwise.
The inhibition of FSH-stimulated cAMP production is expressed as the
percentage of the cAMP response in absence of serum or follicular fluid,
which is set as 100%. Results were evaluated using one-way ANOVA,
comparing responses as percentages of the serum free response. Cor-
relation of follicle characteristics with experimental results were ana-
lyzed using Spearman’s rank order test. P values given are two-sided,
with 0.05 taken as the limit for statistical significance.
Results
Effect of hypogonadotropic human serum
The dose-dependent stimulation of adenylate cyclase in
CHO cells is shown in Fig. 2. Basal levels of cAMP were
0.9–2.1 pmol/mg DNA, and maximally stimulated levels
were 350–4203 higher. The sensitivity, defined as the dose
of recFSH eliciting a response of more than twice the stan-
dard deviation of the basal cAMP production, was 0.4 mIU/
mL. The half-maximal stimulation of cAMP production
(ED50 value) was obtained at a dose of 24.9 mIU/mL FSH.
TABLE 2. Follicles (n 5 83) obtained from 25 normally cycling subjects and 5 PCOS patients, divided into categories on the basis of cycle
day, size, and AD/E2 ratio
Categorya Number Cycle day Size (mm) A/E2 ratio
Normal cycle: I 10 5 6 42
(EFP; ,10 mm; atretic) (2–7) (5–8) (4–238)




III 23 11 6 30
(LFP; ,10 mm, atretic) (8–15) (3–8) (4–256)
IV 4 11 10 127
(LFP; $10 mm; atretic) (9–14) (9–12) (62–173)




PCOS: A 7 5 9.5
(,10 mm; atretic) (5–8) (5.0–46.9)
B 4 7 2.4
(,10 mm; healthy) (3–8) (0.1–3.2)
C 4 17 7.4
($10 mm; atretic) (16–18) (4.3–12.8)
D 10 16 0.1
($10 mm; healthy) (9–20) (0.1–0.7)
a EFP, early follicular phase; LFP, late follicular phase; healthy, AD/E2 ratio , 4; atretic, AD/E2 ratio $ 4. Values given are median and
range.
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The intraassay coefficient of variation, at different stimula-
tory concentrations of FSH, was less than 16%. To study the
effects of serum at different doses of recFSH, CHO cells were
incubated in the presence of different concentrations of hu-
man hypogonadotropic serum (10, 30, and 90% vol/vol) and
stimulated with increasing doses of recFSH (3–100 mIU/
mL). Basal cAMP production was not affected by the addi-
tion of hypogonadotropic serum, whereas in the presence of
90% vol/vol hypogonadotropic serum, stimulated cAMP
production decreased to 49–68% of responses under serum-
free conditions (Fig. 2).
When cAMP response at any given concentration of
recFSH is expressed relative to cAMP production under se-
rum-free conditions, addition of hypogonadotropic serum at
concentrations more than 10% vol/vol inhibits cAMP pro-
duction, independent from the concentration of serum (Fig.
3). At a high FSH concentration (30 mIU/mL), a competition
between FSH and serum components is apparent over the
whole serum concentration range, whereas at low FSH con-
centrations (3 or 6 mIU/mL), this competition occurs only at
serum concentrations less than 3% vol/vol. At serum con-
centrations more than 10% vol/vol, a saturation of the in-
hibitory effect is observed. Despite the slight inhibition by
serum factors, CHO cells remain sensitive to stimulation by
FSH. Even in the presence of 90% vol/vol of hypogonado-
tropic serum, addition of 3 mIU/mL recFSH results in a 5-
to 8-fold stimulation of the cAMP production (data not
shown).
Effects of serum from normal controls, normogonadotropic
anovulatory patients, and PCOS patients
Serum samples obtained from normally cycling individ-
uals or anovulatory patients, with or without PCOS, inhib-
ited cAMP production up to 39 6 4%, 35 6 2%, and 34 6 3%
of the response under serum free conditions, respectively,
when tested at 90% vol/vol. Within each group, a significant
further increase in inhibition was absent (P . 0.38) when
serum concentrations were increased from 10 to 90% vol/vol.
Furthermore, no statistically significant differences were
found between patient groups and normal controls (P .
0.08), with regard to the inhibition of FSH-stimulated cAMP
production at each concentration of serum (Fig. 4).
Effect of follicular fluid from normal controls and PCOS
patients
Adapted bioassay conditions were used to measure the
effects of small amounts of follicular fluid (see Materials and
Methods section). The intraassay coefficient of variation of the
adapted assay was greater (,21%), compared with the 48-
well assay (,16%). FSH-stimulated cAMP production was
clearly inhibited in the presence of 10 or 30% vol/vol of
follicular fluid, although in several samples, a concentration-
dependent decrease in cAMP was not observed. The mean
FIG. 2. cAMP response, expressed as the stimulation factor times
basal production (mean 6 SEM of three assays in triplicate) in CHO
cells, stimulated with increasing concentrations of recFSH in the
presence of 0.1 mmol/L IBMX and increasing concentrations of human
hypogonadotropic serum (F, serum free; E, 10%; , 30%; , 90%
vol/vol).
FIG. 3. Decreased cAMP production by CHO cells, stimulated with 30
mIU/mL (E); 6 mIU/mL (F), or 3 mIU/mL (M) of recFSH, incubated
in the presence of increasing concentrations (3–90% vol/vol) of hy-
pogonadotropic human serum. Results (mean 6 SEM of three exper-
iments in triplicate) are expressed as the percentage of the response
under serum-free conditions (100%).
FIG. 4. cAMP production expressed as percentage of the production
under serum-free conditions (mean 6 SEM of two experiments in
duplicate) by CHO cells, stimulated with a fixed dose of FSH (6
mIU/mL) in the presence of increasing concentrations of serum (3–
90% vol/vol) from regularly cycling women (n 5 8, open bars); nor-
mogonadotropic anovulatory patients without PCOS (n 5 13, hatched
bars); and PCOS patients (n 5 16, solid bars).
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relative cAMP production was lower at a concentration of
30% vol/vol, as compared with 10% vol/vol (55 6 2% and
68 6 2%, respectively; P , 0.001). No differences in inhibition
of the cAMP response were found when comparing various
classes of follicular fluid samples from normally developing
follicles (Fig. 5, upper panel). The inhibitory effect of follicular
fluid did not correlate with follicle size, with the AD/E2 ratio
of the follicular fluid, nor with the menstrual cycle phase in
which the samples were obtained (data not shown). Similar
results were obtained with follicular fluid from PCOS pa-
tients, as compared with follicular fluid from regularly cy-
cling women (Fig. 5, lower panel).
Discussion
Inhibition of FSH action at the level of granulosa cells in
the ovaries may underlie anovulation in women presenting
with normal circulating FSH concentrations. The aim of this
study was to compare levels of FSH receptor inhibitory ac-
tivity in serum and follicular fluid from regularly cycling
women and patients with normogonadotropic anovulation.
The inhibitory activity was assessed by measuring the FSH-
induced adenylate cyclase activity in cultured CHO cells
stably transfected with the human FSH receptor (25). A
similar system has been applied recently to assess bioac-
tive FSH concentrations in serum throughout the men-
strual cycle (34). In the present study, CHO cells were
stimulated with physiological concentrations of FSH in the
presence of untreated serum or follicular fluid. A wide
range of concentrations of serum or follicular fluid was
tested, from 3–90% vol/vol. High concentrations were
applied, to approach protein concentrations that occur
under physiological conditions.
Primary cultures of rat granulosa (35) or Sertoli cells (36)
have been used as in vitro bioassays for FSH. These bio-
assays are hampered by a strong inhibition of the FSH
response caused by unspecified factors in serum. An in-
hibition of more than 80% of the induced E2 response can
be observed in the presence of only 4% serum (25, 35). In
contrast, currently used CHO cells show only a limited
inhibition of FSH-induced cAMP production by serum.
Even in the presence of 90% vol/vol human serum, the
cAMP response is inhibited up to 60% only. Although this
inhibition might be caused by metabolic changes in the
cells, this seems less likely because prolonged incubation
of the cells in serum affected neither cell viability nor basal
cAMP production (25). In addition, the cells can be stim-
ulated to produce large amounts of cAMP despite prein-
cubation in 90% serum (25). It is of interest that in the
presence of serum concentrations more than 10% vol/vol,
the percentage inhibition of FSH-dependent receptor ac-
tivation (at a fixed FSH concentration) is independent of
the concentration of serum. This fixed magnitude of in-
hibition over a wide range of serum concentrations (10 –
90% vol/vol) suggests a saturating effect of the inhibitory
components in serum. On the other hand, the CHO cells
still respond to elevation of the FSH levels, irrespective of
serum concentrations. This suggests that a competition
exists between inhibiting factors and FSH for the FSH
receptor. Although the mechanism of inhibition is unclear,
this may be attributed to a nonspecific protein matrix
effect, because bovine and equine sera show similar inhi-
bition curves (25). Comparing sera from regularly cycling
women with normogonadotropic anovulatory patients
(with or without PCOS) showed no differences in inhib-
itory activity. This argues against the presence of increased
levels of inhibitors of FSH receptor activation in serum
from these patients.
Because factors inhibiting FSH receptor activation may
be present exclusively in the follicular compartment, fol-
licular fluid obtained from individual follicles throughout
the follicular phase of the menstrual cycle and from PCOS
patients also were tested. Follicular fluid samples were
classified according to the stage of the menstrual cycle in
which they were obtained, as well as by size and steroid
content (expressed as the AD/E2 ratio). Different classes
of normally developing follicles did not reveal differences
with regard to inhibition of FSH receptor activation. Nei-
ther did follicular fluid from PCOS patients, compared
FIG. 5. cAMP response in CHO cells stimulated with 3 mU/mL
recFSH in the presence of follicular fluid from regularly cycling
women (upper panel) and PCOS patients (lower panel). The response
is expressed as a percentage of the response in the absence of follicular
fluid. Dots indicate responses of individual samples (tested in dupli-
cate), with a solid line connecting the responses of individual samples
at 10 and 30% vol/vol follicular fluid concentration. Follicle category
in upper panel: I, EFP, ,10 mm, atretic; II, EFP, ,10 mm, healthy;
III, LFP, ,10 mm; IV, LFP, $10 mm, atretic; and V, LFP, healthy.
Follicle category in lower panel: A, ,10 mm, atretic; B, ,10 mm,
healthy; C, $10 mm, atretic; and D, $10 mm, healthy. See also
Table 2.
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with matched control follicles, show any difference in
inhibition of FSH receptor activation. Results obtained
with follicular fluid displayed a larger degree of variation,
compared with results obtained from the addition of se-
rum samples. Part of this variation may be caused by the
higher intraassay coefficient of variation of the assay ap-
plying small volumes. Another explanation may be found
in differences in the endogenous FSH levels of the indi-
vidual follicular fluid samples. In the present study, FSH
content in follicular fluid could not be assessed, because
of the small volumes available. It was therefore not pos-
sible to normalize for potential differences in FSH levels.
In an attempt to limit the variation in FSH levels in the
follicular fluid assays, a small amount of FSH (3 mIU/mL)
was added to each follicular fluid dilution. The choice for
this FSH concentration was on the basis of data from the
literature (4, 8, 29) that report levels of intrafollicular im-
munoreactive FSH ranging between 0.3 and 6 IU/L. This
uncertainty in the final FSH concentration could explain
the reversal of inhibition observed in some samples at
increased concentration. However, despite these uncer-
tainties, the observed responses did not correlate with any
follicle characteristic, such as size or steroid content, or
with menstrual cycle phase or PCOS diagnosis. Although
inhibitory effects of subfractions in serum or follicular
fluid have not been tested separately, the total net effect
of potentially different combinations is similar in both
controls and anovulatory patients. Therefore, it seems un-
likely that FSH receptor inhibition plays a significant role
in the (patho)physiology of normal or disturbed follicle
development.
Specific FSH receptor-binding inhibitors have been de-
scribed in partly purified fractions of human serum and
follicular fluid (19, 23, 37). However, not all FSH-binding
inhibitory activity results in inhibition of FSH, because
part of these binding inhibitors have FSH agonist activity
(22). Results of the present study show that the biological
activity of FSH in the context of serum proteins is approx-
imately 50% of the activity in the absence of serum. The
mechanism underlying this reduction in bioactivity is not
known, but it may be postulated that FSH is partly bound
to plasma proteins with low affinity, thereby reducing the
amount available for receptor activation. On the other
hand, serum proteins also may bind reversibly to the re-
ceptor, thereby reducing the number of receptors available
for interaction with FSH. One other aspect to be considered
is that, in the present study, only adenylate cyclase activity
has been taken as the endpoint of FSH receptor activation.
It is known that FSH receptor activation results in forma-
tion of intracellular messengers other than cAMP, like
calcium ions (38, 39). Although it is not yet clear whether
this Ca21 pathway functions independently from cAMP
(39, 40), it could be postulated that specific FSH receptor
inhibitors have a preference for one pathway, leaving the
other less inhibited, which could thus result in expression
of different cellular functions. Possible inhibition of dif-
ferent pathways is illustrated by findings that immuno-
globulins in serum from women with premature ovarian
failure block FSH-induced DNA synthesis in granulosa
cells in vitro (24), although they do not affect FSH-induced
steroidogenesis (41).
Our conclusion from these in vitro studies that FSH
receptor inhibition is a constant, and therefore may be of
only limited significance for regulation of follicle devel-
opment, is being supported by recent findings from clin-
ical studies. Growth and selection of the dominant follicle
is induced by increasing levels of FSH during the luteo-
follicular transition in the menstrual cycle (42). Although
normogonadotropic anovulatory patients display bioac-
tive and immunoreactive FSH levels comparable with fol-
licular phase levels during the normal menstrual cycle (1,
5), these patients lack the intercycle rise. Normal mono-
follicular development and ovulation can be induced in
normogonadotropic anovulatory patients by the admin-
istration of exogenous FSH, applying a decremental-dose
regimen (6, 43). Although the administration of gonado-
tropins in these patients suggests an increased FSH-
threshold level that needs to be surpassed to ensure follicle
development, it seems that normal follicle development
can be achieved in normogonadotropic anovulatory pa-
tients without increasing FSH to supraphysiological con-
centrations (5). These findings dispute the presence of an
increased FSH-threshold level in normogonadotropic
anovulatory patients, which could be caused by locally
acting factors blocking FSH action. It could well be that the
absence of the transient increase in FSH levels in anovu-
latory patients is an important factor in the etiology of
arrest of follicle development. It may be of interest that, in
particular, bioactive FSH levels increase during the luteo-
follicular transition, as has been demonstrated recently
(34). Although the bioactive-to-immunoactive FSH ratio
remains constant during the EFP in regular cycling women
(5, 34) and is not different in anovulatory patients (5), the
change in FSH levels and the bioactive-to-immunoreactive
ratio in the late luteal phase may be of significance for
follicle recruitment and selection. Furthermore, under nor-
mal conditions, ongoing growth of the dominant follicle
occurs despite decreasing levels of FSH in the LFP (15).
This suggests an enhancement of FSH action, allowing the
dominant follicle to continue its development, whereas
FSH levels drop below the threshold for the remaining,
less mature follicles. This enhancement of FSH action may
be the result of locally active growth factors, such as IGF-I
and -II, and the IGF-binding proteins (13). These factors act
through their own specific receptors and therefore exert
their effect through intracellular pathways and not di-
rectly through the FSH-receptor. The potential signifi-
cance of IGF-II, as an intraovarian factor involved in the
development of the dominant follicle in the human, has
been stressed recently (44).
In conclusion, analysis of inhibition of FSH receptor acti-
vation, by serum or follicular fluid samples from both reg-
ularly cycling women and PCOS patients, indicates that in-
creased levels of FSH receptor inhibitors do not play a
significant role in the regulation of normal and abnormal
follicle development. This is in concert with findings that
normogonadotropic anovulatory patients do not exhibit an
increased FSH-threshold level per se. Both the dynamics in
FSH levels in the EFP and locally active growth factors, acting
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through their own receptors, may be of greater significance
for follicle growth and selection.
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